Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists

Richard M. van Rijn, Daniela I. Brissett, Jennifer Whistler

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: Naltrexone is one of the few drugs approved by the Federal Drug Administration for the treatment of alcoholism. However, naltrexone is only effective in a subpopulation of treatment-seeking alcohol abusers, and suffers from compliance issues. The non-selective nature of this opioid antagonist likely contributes to its side effects and poor therapeutic efficacy. Drugs selectively targeting delta opioid receptor subtypes offer a potential way to treat alcohol abuse disorders. We have recently shown that delta subtype-selective agonists TAN-67 and SNC80 can have opposing effects on alcohol consumption, while having similar effects on alcohol withdrawal-induced anxiety. Methods: We studied the ability of TAN-67 and SNC80 to induce place preference in naïve and ethanol exposed C57BL/6 mice and determined the effect of these agonists on the expression of ethanol place preference. Results: We show that TAN-67 and SNC80 have opposing actions on ethanol place preference. However, neither of the drugs induces place preference by themselves at doses that are therapeutically effective in mice. Interestingly, SNC80, like naltrexone reduces ethanol place preference, however we have previously shown that SNC80 increases ethanol consumption at the tested dose. Similar to naltrexone, TAN-67 reduces alcohol consumption, but we show here that it may be due to an increase in ethanol place preference. Importantly, we found that chronic ethanol exposure does not increase the rewarding properties of the DOR subtype selective agonists. Conclusions: Our results provide a better understanding of how DOR subtype selective drugs could potentially be used for treatment of alcohol abuse disorders.

Original languageEnglish (US)
Pages (from-to)156-159
Number of pages4
JournalDrug and Alcohol Dependence
Volume122
Issue number1-2
DOIs
StatePublished - Apr 1 2012
Externally publishedYes

Fingerprint

delta Opioid Receptor
Ethanol
Modulation
Naltrexone
Alcohols
Alcoholism
Alcohol Drinking
Pharmaceutical Preparations
Aptitude
Narcotic Antagonists
Therapeutic Uses
Drug Delivery Systems
Inbred C57BL Mouse
Compliance
Therapeutics
Anxiety
4-(alpha-(4-allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl)-N,N-diethylbenzamide
TAN 67

Keywords

  • Alcoholism
  • Delta opioid receptor
  • Ethanol
  • Place preference
  • Reward
  • Subtypes

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists. / van Rijn, Richard M.; Brissett, Daniela I.; Whistler, Jennifer.

In: Drug and Alcohol Dependence, Vol. 122, No. 1-2, 01.04.2012, p. 156-159.

Research output: Contribution to journalArticle

@article{caa8ea3d55cb4c33b43eb84ff5af072f,
title = "Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists",
abstract = "Background: Naltrexone is one of the few drugs approved by the Federal Drug Administration for the treatment of alcoholism. However, naltrexone is only effective in a subpopulation of treatment-seeking alcohol abusers, and suffers from compliance issues. The non-selective nature of this opioid antagonist likely contributes to its side effects and poor therapeutic efficacy. Drugs selectively targeting delta opioid receptor subtypes offer a potential way to treat alcohol abuse disorders. We have recently shown that delta subtype-selective agonists TAN-67 and SNC80 can have opposing effects on alcohol consumption, while having similar effects on alcohol withdrawal-induced anxiety. Methods: We studied the ability of TAN-67 and SNC80 to induce place preference in na{\"i}ve and ethanol exposed C57BL/6 mice and determined the effect of these agonists on the expression of ethanol place preference. Results: We show that TAN-67 and SNC80 have opposing actions on ethanol place preference. However, neither of the drugs induces place preference by themselves at doses that are therapeutically effective in mice. Interestingly, SNC80, like naltrexone reduces ethanol place preference, however we have previously shown that SNC80 increases ethanol consumption at the tested dose. Similar to naltrexone, TAN-67 reduces alcohol consumption, but we show here that it may be due to an increase in ethanol place preference. Importantly, we found that chronic ethanol exposure does not increase the rewarding properties of the DOR subtype selective agonists. Conclusions: Our results provide a better understanding of how DOR subtype selective drugs could potentially be used for treatment of alcohol abuse disorders.",
keywords = "Alcoholism, Delta opioid receptor, Ethanol, Place preference, Reward, Subtypes",
author = "{van Rijn}, {Richard M.} and Brissett, {Daniela I.} and Jennifer Whistler",
year = "2012",
month = "4",
day = "1",
doi = "10.1016/j.drugalcdep.2011.09.024",
language = "English (US)",
volume = "122",
pages = "156--159",
journal = "Drug and Alcohol Dependence",
issn = "0376-8716",
publisher = "Elsevier Ireland Ltd",
number = "1-2",

}

TY - JOUR

T1 - Distinctive modulation of ethanol place preference by delta opioid receptor-selective agonists

AU - van Rijn, Richard M.

AU - Brissett, Daniela I.

AU - Whistler, Jennifer

PY - 2012/4/1

Y1 - 2012/4/1

N2 - Background: Naltrexone is one of the few drugs approved by the Federal Drug Administration for the treatment of alcoholism. However, naltrexone is only effective in a subpopulation of treatment-seeking alcohol abusers, and suffers from compliance issues. The non-selective nature of this opioid antagonist likely contributes to its side effects and poor therapeutic efficacy. Drugs selectively targeting delta opioid receptor subtypes offer a potential way to treat alcohol abuse disorders. We have recently shown that delta subtype-selective agonists TAN-67 and SNC80 can have opposing effects on alcohol consumption, while having similar effects on alcohol withdrawal-induced anxiety. Methods: We studied the ability of TAN-67 and SNC80 to induce place preference in naïve and ethanol exposed C57BL/6 mice and determined the effect of these agonists on the expression of ethanol place preference. Results: We show that TAN-67 and SNC80 have opposing actions on ethanol place preference. However, neither of the drugs induces place preference by themselves at doses that are therapeutically effective in mice. Interestingly, SNC80, like naltrexone reduces ethanol place preference, however we have previously shown that SNC80 increases ethanol consumption at the tested dose. Similar to naltrexone, TAN-67 reduces alcohol consumption, but we show here that it may be due to an increase in ethanol place preference. Importantly, we found that chronic ethanol exposure does not increase the rewarding properties of the DOR subtype selective agonists. Conclusions: Our results provide a better understanding of how DOR subtype selective drugs could potentially be used for treatment of alcohol abuse disorders.

AB - Background: Naltrexone is one of the few drugs approved by the Federal Drug Administration for the treatment of alcoholism. However, naltrexone is only effective in a subpopulation of treatment-seeking alcohol abusers, and suffers from compliance issues. The non-selective nature of this opioid antagonist likely contributes to its side effects and poor therapeutic efficacy. Drugs selectively targeting delta opioid receptor subtypes offer a potential way to treat alcohol abuse disorders. We have recently shown that delta subtype-selective agonists TAN-67 and SNC80 can have opposing effects on alcohol consumption, while having similar effects on alcohol withdrawal-induced anxiety. Methods: We studied the ability of TAN-67 and SNC80 to induce place preference in naïve and ethanol exposed C57BL/6 mice and determined the effect of these agonists on the expression of ethanol place preference. Results: We show that TAN-67 and SNC80 have opposing actions on ethanol place preference. However, neither of the drugs induces place preference by themselves at doses that are therapeutically effective in mice. Interestingly, SNC80, like naltrexone reduces ethanol place preference, however we have previously shown that SNC80 increases ethanol consumption at the tested dose. Similar to naltrexone, TAN-67 reduces alcohol consumption, but we show here that it may be due to an increase in ethanol place preference. Importantly, we found that chronic ethanol exposure does not increase the rewarding properties of the DOR subtype selective agonists. Conclusions: Our results provide a better understanding of how DOR subtype selective drugs could potentially be used for treatment of alcohol abuse disorders.

KW - Alcoholism

KW - Delta opioid receptor

KW - Ethanol

KW - Place preference

KW - Reward

KW - Subtypes

UR - http://www.scopus.com/inward/record.url?scp=84858446783&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84858446783&partnerID=8YFLogxK

U2 - 10.1016/j.drugalcdep.2011.09.024

DO - 10.1016/j.drugalcdep.2011.09.024

M3 - Article

VL - 122

SP - 156

EP - 159

JO - Drug and Alcohol Dependence

JF - Drug and Alcohol Dependence

SN - 0376-8716

IS - 1-2

ER -